SubsidieMeestersScalable and Eco-friendly Bioproduction
Core Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins.
Projectdetails
Introduction
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins.
Application
The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy.
Innovation
The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems by offering:
- A 25-fold yield increase
- A 10-fold cost reduction
Potential
Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity, as plants are well known to be the most promising system for production upscaling.
Ambition
Core Biogenesis’s ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.153.390 |
| Totale projectbegroting | € 1.647.700 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CORE BIOGENESISpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approachAlkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The scale-up of the BioMilk platform: The revolutionary approach to manufacturing of biopharmaceuticalsBio-Sourcing aims to revolutionize biosimilar production with its BioMilk platform, leveraging CRISPR-engineered goats for cost-effective, sustainable manufacturing and securing licensing deals by 2027. | EIC Accelerator | € 2.475.890 | 2024 | Details |
Biosensor Activated Biomanufacturing Scale-upEnduro aims to revolutionize microbial biomanufacturing with its synthetic biology plugin, Enduro Sense, to enable scalable processes and attract investment for commercial deployment. | EIC Accelerator | € 1.815.295 | 2023 | Details |
SBMP - disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrierCellevate's SBMP-microcarriers use innovative nanofibrous technology to enhance adherent cell culture in bioreactors, significantly improving biopharmaceutical production efficiency and quality. | EIC Accelerator | € 2.485.857 | 2022 | Details |
Using biotechnology to create the next generation of sustainable foods from the roots of mushroomsMushlabs uses proprietary fermentation technology to cultivate mycelium into a sustainable, protein-rich meat alternative, aiming to transform plant-based diets. | EIC Accelerator | € 2.426.375 | 2022 | Details |
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach
Alkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028.
The scale-up of the BioMilk platform: The revolutionary approach to manufacturing of biopharmaceuticals
Bio-Sourcing aims to revolutionize biosimilar production with its BioMilk platform, leveraging CRISPR-engineered goats for cost-effective, sustainable manufacturing and securing licensing deals by 2027.
Biosensor Activated Biomanufacturing Scale-up
Enduro aims to revolutionize microbial biomanufacturing with its synthetic biology plugin, Enduro Sense, to enable scalable processes and attract investment for commercial deployment.
SBMP - disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrier
Cellevate's SBMP-microcarriers use innovative nanofibrous technology to enhance adherent cell culture in bioreactors, significantly improving biopharmaceutical production efficiency and quality.
Using biotechnology to create the next generation of sustainable foods from the roots of mushrooms
Mushlabs uses proprietary fermentation technology to cultivate mycelium into a sustainable, protein-rich meat alternative, aiming to transform plant-based diets.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Haalbaarheidsstudie voor een groeifactorproductiebedrijfHet project richt zich op het verlagen van de kosten van groeifactoren voor kweekvleesproductie door deze op grotere schaal te produceren, ter ondersteuning van de eiwittransitie. | Mkb-innovati... | € 20.000 | 2022 | Details |
Genetisch gemodificeerde micro-organismen op een bio-based dieetEV Biotech onderzoekt de haalbaarheid van genetisch gemodificeerde micro-organismen die zetmeel kunnen afbreken voor duurzame biomolecuulproductie, ter vervanging van dure glucose. | Mkb-innovati... | € 20.000 | 2023 | Details |
Bioraffinage van eiwitstrengen uit biomassa tbv. Pharma en (bulk)chemieHet project richt zich op het ontwikkelen van processen voor het winnen van eiwitten uit biomassa, gericht op duurzame toepassingen in de chemie en farmacie, ter ondersteuning van de groeiende vraag naar eiwitten. | Mkb-innovati... | € 20.000 | 2021 | Details |
Translating a new metabolic engineering strategy to industrial biotech applicationsThe TRANSMETECH project aims to translate the StrainBooster metabolic engineering strategy into industrial applications, enhancing bioprocess efficiency for sustainable chemical production. | ERC Proof of... | € 150.000 | 2023 | Details |
BioMaxBioMax ontwikkelt innovatieve biopesticides door een snelle analysemethode en nieuwe celvrije bestrijdingsmiddelen te creëren. | Mkb-innovati... | € 108.570 | 2023 | Details |
Haalbaarheidsstudie voor een groeifactorproductiebedrijf
Het project richt zich op het verlagen van de kosten van groeifactoren voor kweekvleesproductie door deze op grotere schaal te produceren, ter ondersteuning van de eiwittransitie.
Genetisch gemodificeerde micro-organismen op een bio-based dieet
EV Biotech onderzoekt de haalbaarheid van genetisch gemodificeerde micro-organismen die zetmeel kunnen afbreken voor duurzame biomolecuulproductie, ter vervanging van dure glucose.
Bioraffinage van eiwitstrengen uit biomassa tbv. Pharma en (bulk)chemie
Het project richt zich op het ontwikkelen van processen voor het winnen van eiwitten uit biomassa, gericht op duurzame toepassingen in de chemie en farmacie, ter ondersteuning van de groeiende vraag naar eiwitten.
Translating a new metabolic engineering strategy to industrial biotech applications
The TRANSMETECH project aims to translate the StrainBooster metabolic engineering strategy into industrial applications, enhancing bioprocess efficiency for sustainable chemical production.
BioMax
BioMax ontwikkelt innovatieve biopesticides door een snelle analysemethode en nieuwe celvrije bestrijdingsmiddelen te creëren.